DEPARTMENT OF HEALTH AND HUMAN SERVICES FORM APPROVED
CENTERS FOR MEDICARE AND MEDICAID SERVICES OMB No. 0938-0046
Item 17. Primary Cause of Renal Failure should be completed by the attending physician from the list below. Enter the ICD-10-CM code to indicate the primary cause of end stage renal disease. If there are several probable causes of renal failure, choose one as primary. An ICD-10-CM code is effective as of February 1 2022.
E10.22 Type 1 diabetes mellitus with diabetic chronic
kidney disease
E10.29 Type 1 diabetes mellitus with other diabetic kidney complication
E11.21 Type 2 diabetes mellitus with diabetic nephropathy
E11.22 Type 2 diabetes mellitus with diabetic chronic kidney disease
E11.29 Type 2 diabetes mellitus with other diabetic kidney complication
N00.8 Acute nephritic syndrome with other morphologic changes
N01.9 Rapidly progressive nephritic syndrome with unspecified morphologic changes
N02.8 Recurrent and persistent hematuria with other morphologic changes
N03.0 Chronic nephritic syndrome with minor glomerular abnormality
N03.1 Chronic nephritic syndrome with focal and segmental glomerular lesions
N03.2 Chronic nephritic syndrome with diffuse membranous glomerulonephritis
N03.3 Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis
N03.4 Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis
N03.5 Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
N03.6 Chronic nephritic syndrome with dense deposit disease
N03.7 Chronic nephritic syndrome with diffuse crescentic glomerulonephritis
N03.8 Chronic nephritic syndrome with other morphologic changes
N03.9 Chronic nephritic syndrome with unspecified morphologic changes
N04.0 Nephrotic syndrome with minor glomerular abnormality
N04.1 Nephrotic syndrome with focal and segmental glomerular lesions
N04.2 Nephrotic syndrome with diffuse membranous glomerulonephritis
N04.3 Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis
N04.4 Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis
N04.5 Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis
N04.6 Nephrotic syndrome with dense deposit disease
N04.7 Nephrotic syndrome with diffuse crescentic glomerulonephritis
N04.8 Nephrotic syndrome with other morphologic changes
N04.9 Nephrotic syndrome with unspecified morphologic changes
N05.9 Unspecified nephritic syndrome with unspecified morphologic changes
N07.0 Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality
N10 Acute tubulo-interstitial nephritis
N11.9 Chronic tubulo-interstitial nephritis, unspecified
N13.70 Vesicoureteral-reflux, unspecified
N13.8 Other obstructive and reflux uropathy 2
T86.00 Unspecified complication of bone marrow transplant
T86.10 Unspecified complication of kidney transplant
T86.20 Unspecified complication of heart transplant
T86.40 Unspecified complication of liver transplant
T86.819 Unspecified complication of lung transplant
T86.859 Unspecified complication of intestine transplant
T86.899 Unspecified complication of other transplanted tissue
HYPERTENSION/LARGE VESSEL DISEASE
I12.0 Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease
I12.9 Hypertensive chronic kidney disease with stage 1through stage 4 chronic kidney disease, or unspecified chronic kidney disease
I15.0 Renovascular hypertension
I15.8 Other secondary hypertension
I75.81 Atheroembolism of kidney
E72.04 Cystinosis
E72.53 Hyperoxaluria
E75.21 Fabry (-Anderson) disease
N07.8 Hereditary nephropathy, not elsewhere classified with other morphologic lesions
N31.9 Neuromuscular dysfunction of bladder, unspecified
Q56.0 Hermaphroditism, not elsewhere classified
Q60.2 Renal agenesis, unspecified
Q61.19 Other polycystic kidney, infantile type
Q61.2 Polycystic kidney, adult type
Q61.4 Renal dysplasia
Q61.5 Medullary cystic kidney
Q61.8 Other cystic kidney diseases
Q62.11 Congenital occlusion of ureteropelvic junction
Q62.12 Congenital occlusion of ureterovesical orifice
Q63.8 Other specified congenital malformation of kidney
Q64.2 Congenital posterior urethral valves
Q79.4 Prune belly syndrome
Q85.1 Tuberous sclerosis
Q86.8 Other congenital malformation syndromes due to known exogenous causes
Q87.1 Congenital malformation syndromes predominantly associated with short stature
Q87.81 Alport syndrome
C64.9 Malignant neoplasm of unspecified kidney, except renal pelvis
C80.1 Malignant (primary) neoplasm, unspecified
C85.93 Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C88.2 Heavy chain disease
C90.00 Multiple myeloma not having achieved remission
D30.9 Benign neoplasm of urinary organ, unspecified
D41.00 Neoplasm of uncertain behavior of unspecified kidney
D41.9 Neoplasm of uncertain behavior of unspecified urinary organ
E85.9 Amyloidosis, unspecified
N05.8 Unspecified nephritic syndrome with other morphologic changes
E83.52 Hypercalcemia
D59.3 Hemolytic-uremic syndrome
D69.0 Allergic purpura
I77.89 Other specified disorders of arteries and arterioles
M31.0 Hypersensitivity angiitis
M31.1 Thrombotic microangiopathy
M31.31 Wegener’s granulomatosis with renal involvement
M31.7 Microscopic polyangiitis
M32.0 Drug-induced systemic lupus erythematosus
M32.10 Systemic lupus erythematosus, organ or system involvement unspecified
M32.14 Glomerular disease in systemic lupus erythematosus
M32.15 Tubulo-interstitial nephropathy in systemic lupus erythematosus
M34.89 Other systemic sclerosis
A18.10 Tuberculosis of genitourinary system, unspecified
N28.9 Disorder of kidney and ureter, unspecified
N17.0 Acute kidney failure with tubular necrosis
N17.1 Acute kidney failure with acute cortical necrosis
N17.9 Acute kidney failure, unspecified
B20 Human immunodeficiency virus [HIV] disease
D57.1 Sickle-cell disease without crisis
D57.3 Sickle cell trait
I50.9 Heart failure, unspecified
K76.7 Hepatorenal syndrome
M10.30 Gout due to renal impairment, unspecified site
N14.0 Analgesic nephropathy
N14.1 Nephropathy induced by other drugs, medicaments and biological substances
N14.3 Nephropathy induced by heavy metals
N20.0 Calculus of kidney
N25.89 Other disorders resulting from impaired renal tubular function
N26.9 Renal sclerosis, unspecified
N28.0 Ischemia and infarction of kidney
N28.89 Other specified disorders of kidney and ureter
O90.4 Postpartum acute kidney failure
S37.009A Unspecified injury of unspecified kidney, initial encounter
Z90.5 Acquired Absence of Kidney
U07.1 COVID19
INSTRUCTIONS FOR COMPLETION OF END STAGE RENAL DISEASE MEDICAL EVIDENCE REPORT MEDICARE ENTITLEMENT AND/OR PATIENT REGISTRATION |
Submission of CMS-2728 Form:
|
For whom should this form be completed: This form SHOULD NOT be completed for those patients who are in acute renal failure. Acute renal failure is a condition in which kidney function can be expected to recover after a short period of dialysis, i.e., several weeks or months. This form MUST BE completed within 45 days for ALL patients beginning any of the following: Check the appropriate block that identifies the reason for submission of this form.
InitialFor all patients who initially receive a kidney transplant instead of a course of dialysis. For patients for whom a regular course of dialysis has been prescribed by a physician because they have reached that stage of renal impairment that a kidney transplant or regular course of dialysis is necessary to maintain life. The first date of a regular course of dialysis is the date this prescription is implemented whether as an inpatient of a hospital, an outpatient in a dialysis center or facility, or a home patient. The form should be completed for all patients in this category even if the patient dies within this time period.
Re-entitlementFor beneficiaries who have already been entitled to ESRD Medicare benefits and those benefits were terminated because their coverage stopped 3 years post-transplant but now are again applying for Medicare ESRD benefits because they returned to dialysis or received another kidney transplant. For beneficiaries who stopped dialysis for more than 12 months, have had their Medicare ESRD benefits terminated and now returned to dialysis or received a kidney transplant. These patients will be reapplying for Medicare ESRD benefits.
SupplementalPatient has received a transplant or trained for self-care dialysis within the first 3 months of the first date of dialysis and initial form was submitted.
|
Not Hispanic or Latino—A person of culture or origin not described below, regardless of race. Hispanic or Latino—A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin regardless of race. Please complete Item 11 and provide the country, area of origin, or ancestry to which the patient claims to belong.
Definitions of the racial categories for Federal statistics are as follows: American Indian/Alaska Native—A person having origins in any of the original peoples of North and South America (including Central America) and who maintains tribal affiliation or community attachment. Asian—A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. Black or African American—A person having origins in any of the Black racial groups of Africa. Middle Eastern or North African – A person having origins in any of the original peoples of Lebanese, Iranian, Egyptian, Syrian, Moroccan and Israeli Native Hawaiian or Other Pacific Islander—A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. White—A person having origins in any of the original peoples of Europe. Other Race—For respondents unable to identify with any of these five race categories If the patient identifies as American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander complete the name of the enrolled or principal tribe.
Employer Group Health Insurance—Patient receives medical benefits through an employee health plan that covers employees, former employees, or the families of employees or former employees. Medicare—Patient is currently entitled to Federal Medicare benefits. Medicaid—Patient is currently receiving State Medicaid benefits. Veterans Administration—Patient is receiving medical care from a Department of Veterans Affairs facility. Medicare Advantage—Patient is receiving medical benefits under a Medicare Advantage (Medicare Part A and Part B coverage offered by Medicare-approved private companies that must follow rules set by Medicare) organization. Other Medical Insurance—Patient is receiving medical benefits under a health insurance plan that is not Medicare, Medicaid, Department of Veterans Affairs, Medicare Advantage, nor an employer group health insurance plan. Examples of other medical insurance are Railroad Retirement and CHAMPUS beneficiaries or that obtains insurance through the Marketplace. None—Patient has no medical insurance plan.
code. Enter the ICD-10-CM code from page 4 or 6 of form to indicate the primary cause of end stage renal disease. If there are several probable causes of renal failure, choose one as primary. An ICD-10-CM code is effective as of February 1, 2022. These are the only acceptable causes of end stage renal disease.
To
be
completed
by
the
attending
physician.
Check
all
co-morbid conditions that apply. *Cerebrovascular Disease includes history of stroke/ cerebrovascular accident (CVA) and transient ischemic attack (TIA). *Peripheral Vascular Disease includes absent foot pulses, prior typical claudication, amputations for vascular disease, gangrene and aortic aneurysm. *Drug dependence means dependent on illicit drugs. *Inability to ambulate includes an impairment(s) that interferes very seriously with the individual's ability to independently initiate or sustain ambulation *Inability to transfer from bed to chair, or chair to chair, or chair to bed *Needs assistance with daily activities including basic physical needs, comprised the following areas: grooming/personal hygiene, dressing, toileting/continence, and eating The section titled “Consider for Pediatric Patients” should only be used for pediatric patients.
NOTE: For those patients re-entering the Medicare program after benefits were terminated, items in question 21 should contain initial laboratory values within 45 days prior to the most recent ESRD episode (item 26). If a dialysis facility is unable to obtain the laboratory values from the appropriate care setting within 30 days, the dialysis facility may use admission laboratory values drawn prior to initiating the first treatment at the facility LDL and HbA1c should be within 1 year of the most recent ESRD episode (item 35). These tests may not be required for patients under 21 years of age (LDL or HbA1c unless the child is a diabetic).
(b) Enter the lower limit of the normal range for serum albumin from the laboratory which performed the serum albumin test entered in Serum Albumin.
(c) Enter the serum albumin lab method used (BCG or BCP). (d) Enter the serum creatinine value (mg/dl) and date test was taken. THIS FIELD MUST BE COMPLETED. Value must be within 45 days prior to first dialysis treatment or kidney transplant. If a dialysis facility is unable to obtain the laboratory values from the appropriate care setting within 30 days, the dialysis facility may use admission laboratory values drawn prior to initiating the first treatment at the facility. (e) Enter the hemoglobin value (g/dl) and date test was taken. This value and date must be within 45 days prior to the first dialysis treatment or kidney transplant. If a dialysis facility is unable to obtain the laboratory values from the appropriate care setting within 30 days, the dialysis facility may use admission laboratory values drawn prior to initiating the first treatment at the facility. (f) Enter the HbA1c value and the date the test was taken. The date must be within 1 year prior to the first dialysis treatment or kidney transplant. (g) Enter the LDL value with date test was taken. The date must be within 1 year prior to the first dialysis treatment or kidney transplant. (h) Cystatin C value (mg/l) and date test was taken. This value and date must be within 45 days prior to first dialysis treatment or kidney transplant.
SNF/LTC: Check this box only if a patient is residing in a Medicare certified skilled nursing facility and/or long-term care facility and receiving dialysis within the nursing facility. Dialysis may be performed by patient, family, nursing facility staff, or home dialysis staff, but the patient is not transported outside the facility to receive dialysis. Note: Transitional Care Unit is not included in item 32 as it is not anticipated that it will become the long-term treatment center. It is included in item 50 because it can be a current setting when a transplant rejection occurs.
NOTE: For these purposes, end stage renal disease means irreversible damage to a person’s kidneys so severely affecting his/her/their ability to remove or adjust blood wastes that in order to maintain life he/she/they must have either a course of dialysis or a kidney transplant to maintain life. If re-entering the Medicare program, enter beginning date of the current ESRD episode. Note in Remarks, Item 74, that patient is restarting dialysis.
Self-dialysis Training Patients (Medicare Applicants Only) Normally, Medicare entitlement begins with the third month after the month a patient begins a regular course of dialysis treatment. This 3-month qualifying period may be waived if a patient begins a self-dialysis training program in a Medicare approved training facility and is expected to self-dialyze after the completion of the training program. Please complete items 51-58 if the patient has entered into a self-dialysis training program. Items 51-58 must be completed if the patient is applying for a Medicare waiver of the 3-month qualifying period for dialysis benefits based on participation in a self-care dialysis training program.
|
Form CMS-2728-U3 (10/2022)
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
Author | LISA REES |
File Modified | 0000-00-00 |
File Created | 2023-12-12 |